These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 30526555)
1. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555 [TBL] [Abstract][Full Text] [Related]
2. Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients. Saizonou I; Lascombe I; Monnien F; Bedgedjian I; Kleinclauss F; Algros MP; Fauconnet S Sci Rep; 2024 Jul; 14(1):15390. PubMed ID: 38965292 [TBL] [Abstract][Full Text] [Related]
3. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802 [TBL] [Abstract][Full Text] [Related]
4. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Ohlsson G; Moreira JM; Gromov P; Sauter G; Celis JE Mol Cell Proteomics; 2005 Apr; 4(4):570-81. PubMed ID: 15734831 [TBL] [Abstract][Full Text] [Related]
5. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study. Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824 [TBL] [Abstract][Full Text] [Related]
6. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A; Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276 [TBL] [Abstract][Full Text] [Related]
7. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Boiteux G; Lascombe I; Roche E; Plissonnier ML; Clairotte A; Bittard H; Fauconnet S Int J Cancer; 2009 Apr; 124(8):1820-8. PubMed ID: 19115207 [TBL] [Abstract][Full Text] [Related]
8. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708 [TBL] [Abstract][Full Text] [Related]
9. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286 [TBL] [Abstract][Full Text] [Related]
15. Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). Spachmann PJ; Azzolina V; Weber F; Evert M; Eckstein M; Denzinger S; Burger M; Otto W; Breyer J Pathol Oncol Res; 2020 Jul; 26(3):1625-1632. PubMed ID: 31506803 [TBL] [Abstract][Full Text] [Related]
16. Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance. López JI; Angulo JC Int Urol Nephrol; 2009 Dec; 41(4):847-54. PubMed ID: 19283508 [TBL] [Abstract][Full Text] [Related]
17. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer. Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769 [TBL] [Abstract][Full Text] [Related]
18. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660 [TBL] [Abstract][Full Text] [Related]
19. Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer. Minner S; De Silva C; Rink M; Dahlem R; Chun F; Fisch M; Höppner W; Wagner W; Bokemeyer C; Terracciano L; Simon R; Sauter G; Wilczak W Pathology; 2012 Aug; 44(5):448-52. PubMed ID: 22772340 [TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]